{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:37:45Z","timestamp":1759588665739,"version":"3.37.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We previously reported that early arthritis (EA) patients with low vasoactive intestinal peptide (VIP) serum levels demonstrate a worse clinical disease course. In this study, we analysed whether variants in the <jats:italic>VIP<\/jats:italic> gene correlated with its serum levels and clinical EA parameters. The <jats:italic>VIP<\/jats:italic> gene was sequenced in patients with extremely high\/low VIP levels, measured by enzyme immunoassay. Sixteen single nucleotide polymorphisms (SNPs) were differentially distributed between both groups, which were subsequently genotyped in two patients\u2019 sets. We observed that patients with rs688136 CC genotype showed higher VIP levels in both discovery (n\u2009=\u200991; p\u2009=\u20090.033) and validation populations (n\u2009=\u2009131; p\u2009=\u20090.007). This effect was attenuated by the presence of minor alleles rs35643203 and rs12201140, which showed a clear trend towards low VIP level association (p\u2009=\u20090.118 and p\u2009=\u20090.049, respectively). Functional studies with miR-205-5p, which has a target site in the 3\u2032 UTR close to rs688136, revealed a miRNA-mediated regulatory mechanism explaining the higher <jats:italic>VIP<\/jats:italic> gene expression in homozygous patients. Moreover, patients with an rs688136 CC genotype and no minor alleles of the other polymorphisms required less treatment (p\u2009=\u20090.009). We concluded that the identification of polymorphisms associated with VIP serum levels would complement the clinical assessment of the disease severity in rheumatoid arthritis patients.<\/jats:p>","DOI":"10.1038\/s41598-018-20400-6","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T10:31:21Z","timestamp":1516962681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis"],"prefix":"10.1038","volume":"8","author":[{"given":"Iria V.","family":"Seoane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9096-3780","authenticated-orcid":false,"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmina","family":"Juarranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa C.","family":"Talayero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidoro","family":"Gonz\u00e1lez-\u00c1lvaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-1923","authenticated-orcid":false,"given":"Rosa P.","family":"Gomariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Lamana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"20400_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/rheumatology\/ket414","volume":"53","author":"DE Furst","year":"2014","unstructured":"Furst, D. E. & Emery, P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 53, 1560\u20131569 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"20400_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","volume":"43","author":"AJ MacGregor","year":"2000","unstructured":"MacGregor, A. J. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43, 30\u201337 (2000).","journal-title":"Arthritis Rheum."},{"key":"20400_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.rdc.2012.04.002","volume":"38","author":"EW Karlson","year":"2012","unstructured":"Karlson, E. W. & Deane, K. Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 38, 405\u2013426 (2012).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"20400_CR4","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/art.39630","volume":"68","author":"JA Sparks","year":"2016","unstructured":"Sparks, J. A. et al. Associations of smoking and age with inflammatory joint signs among unaffected first-degree relatives of rheumatoid arthritis patients: Results from studies of the etiology of rheumatoid arthritis. Arthritis Rheum 68, 1828\u20131838 (2016).","journal-title":"Arthritis Rheum"},{"key":"20400_CR5","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1007\/s10067-016-3383-x","volume":"35","author":"J He","year":"2016","unstructured":"He, J. et al. Dietary intake and risk of rheumatoid arthritis-a cross section multicenter study. Clin. Rheumatol. 35, 2901\u20132908 (2016).","journal-title":"Clin. Rheumatol."},{"key":"20400_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos, Y. & Drosos, A. A. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 4, 130\u2013136 (2005).","journal-title":"Autoimmun. Rev."},{"key":"20400_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott, D. L., Wolfe, F. & Huizinga, T. W. Rheumatoid arthritis. Lancet 376, 1094\u20131108 (2010).","journal-title":"Lancet"},{"key":"20400_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","volume":"73","author":"JA van Nies","year":"2014","unstructured":"van Nies, J. A. et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann. Rheum. Dis. 73, 861\u2013870 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"20400_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","volume":"74","author":"JA Van Nies","year":"2015","unstructured":"van Nies, J. A., Tsonaka, R., Gaujoux-Viala, C. & Fautrel, B. & van der Helm-van Mil, A. H. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann. Rheum. Dis. 74, 806\u2013812 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"20400_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1381612820666140825123104","volume":"21","author":"I Gonz\u00e1lez-\u00c1lvaro","year":"2015","unstructured":"Gonz\u00e1lez-\u00c1lvaro, I. et al. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Curr. Pharm. Des. 21, 170\u2013181 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"20400_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/gast.2003.50141","volume":"124","author":"C Abad","year":"2003","unstructured":"Abad, C. et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn\u2019s disease. Gastroenterology 124, 961\u2013971 (2003).","journal-title":"Gastroenterology"},{"key":"20400_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10875-006-9042-2","volume":"26","author":"H Li","year":"2006","unstructured":"Li, H., Mei, Y., Wang, Y. & Xu, L. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J. Clin. Immunol. 26, 430\u2013437 (2006).","journal-title":"J. Clin. Immunol."},{"key":"20400_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2005.038232","volume":"65","author":"BM Lodde","year":"2006","unstructured":"Lodde, B. M. et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren\u2019s syndrome. Ann. Rheum. Dis. 65, 195\u2013200 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"20400_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/icb.2010.29","volume":"88","author":"R Jimeno","year":"2010","unstructured":"Jimeno, R. et al. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol. Cell Biol. 88, 734\u2013745 (2010).","journal-title":"Immunol. Cell Biol."},{"key":"20400_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/87887","volume":"7","author":"M Delgado","year":"2001","unstructured":"Delgado, M., Abad, C., Mart\u00ednez, C., Leceta, J. & Gomariz, R. P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7, 563\u2013568 (2001).","journal-title":"Nat. Med."},{"key":"20400_CR16","doi-asserted-by":"crossref","unstructured":"Carri\u00f3n, M. et al. VIP impairs acquisition of the macrophage proinflammatory polarization profile. J. Leukoc. Biol. 100(6), 1385\u20131393 (2016).","DOI":"10.1189\/jlb.3A0116-032RR"},{"key":"20400_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/1381612033455116","volume":"9","author":"D Ganea","year":"2003","unstructured":"Ganea, D. & Delgado, M. The neuropeptides VIP\/PACAP and T cells: inhibitors or activators? Curr. Pharm. Des. 9, 997\u20131004 (2003).","journal-title":"Curr. Pharm. Des."},{"key":"20400_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12031-014-0318-3","volume":"54","author":"R Jimeno","year":"2014","unstructured":"Jimeno, R. et al. Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells. J. Mol. Neurosci. 54, 512\u2013525 (2014).","journal-title":"J. Mol. Neurosci."},{"key":"20400_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1189\/jlb.3A0714-327R","volume":"98","author":"R Jimeno","year":"2015","unstructured":"Jimeno, R. et al. Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect. J. Leukoc. Biol. 98, 257\u2013269 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"20400_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.200909-1451OC","volume":"182","author":"A Prasse","year":"2010","unstructured":"Prasse, A. et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am. J. Respir. Crit. Care Med. 182, 540\u2013548 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"20400_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/apha.12427","volume":"213","author":"D Ganea","year":"2015","unstructured":"Ganea, D., Hooper, K. M. & Kong, W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol. (Oxf.) 213, 442\u2013452 (2015).","journal-title":"Acta Physiol. (Oxf.)"},{"key":"20400_CR22","doi-asserted-by":"publisher","first-page":"e85248","DOI":"10.1371\/journal.pone.0085248","volume":"9","author":"C Mart\u00ednez","year":"2014","unstructured":"Mart\u00ednez, C. et al. Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. PLoS One 9, e85248 (2014).","journal-title":"PLoS One"},{"key":"20400_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12031-015-0517-6","volume":"56","author":"IV Seoane","year":"2015","unstructured":"Seoane, I. V. et al. Vasoactive intestinal peptide in early spondyloarthritis: Low serum levels as a potential biomarker for disease severity. J. Mol. Neurosci. 56, 577\u2013584 (2015).","journal-title":"J. Mol. Neurosci."},{"key":"20400_CR24","doi-asserted-by":"crossref","unstructured":"International Human Genome Sequencing, C. Finishing the euchromatic sequence of the human genome. Nature 431, 931\u2013945 (2004).","DOI":"10.1038\/nature03001"},{"key":"20400_CR25","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1126\/science.1069424","volume":"296","author":"SB Gabriel","year":"2002","unstructured":"Gabriel, S. B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225\u20132229 (2002).","journal-title":"Science"},{"key":"20400_CR26","unstructured":"Toledano, E. et al. Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study. Clin. Exp. Rheumatol (2017)."},{"key":"20400_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0025-7753(02)72526-8","volume":"118","author":"I Gonzalez-Alvaro","year":"2002","unstructured":"Gonzalez-Alvaro, I., Hernandez-Garcia, C., Villaverde Garcia, V., Vargas, E. & Ortiz, A. M. Variations in the drug treatment of rheumatoid arthritis in Spain. Med. Clin. (Barc.) 118, 771\u2013776 (2002).","journal-title":"Med. Clin. (Barc.)"},{"key":"20400_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrrheum.2012.237","volume":"9","author":"S Viatte","year":"2013","unstructured":"Viatte, S., Plant, D. & Raychaudhuri, S. Genetics and epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 141\u2013153 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"20400_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00726-011-1184-8","volume":"45","author":"M Delgado","year":"2013","unstructured":"Delgado, M. & Ganea, D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids 45, 25\u201339 (2013).","journal-title":"Amino Acids"},{"key":"20400_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1196\/annals.1317.031","volume":"1070","author":"RP Gomariz","year":"2006","unstructured":"Gomariz, R. P. et al. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. NY Acad. Sci. 1070, 51\u201374 (2006).","journal-title":"Ann. NY Acad. Sci."},{"key":"20400_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1381612013398374","volume":"7","author":"RP Gomariz","year":"2001","unstructured":"Gomariz, R. P., Mart\u00ednez, C., Abad, C., Leceta, J. & Delgado, M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 7, 89\u2013111 (2001).","journal-title":"Curr. Pharm. Des."},{"key":"20400_CR32","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","volume":"115","author":"SI Said","year":"2007","unstructured":"Said, S. I. et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115, 1260\u20131268 (2007).","journal-title":"Circulation"},{"key":"20400_CR33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/rheumatology\/keh061","volume":"43","author":"MG Juarranz","year":"2004","unstructured":"Juarranz, M. G. et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 43, 416\u2013422 (2004).","journal-title":"Rheumatology (Oxford)"},{"key":"20400_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/rheumatology\/kei219","volume":"45","author":"I Guti\u00e9rrez-Ca\u00f1as","year":"2006","unstructured":"Guti\u00e9rrez-Ca\u00f1as, I. et al. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) 45, 527\u2013532 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"20400_CR35","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/art.30294","volume":"63","author":"M Carri\u00f3n","year":"2011","unstructured":"Carri\u00f3n, M. et al. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum. 63, 1626\u20131636 (2011).","journal-title":"Arthritis Rheum."},{"key":"20400_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.bbi.2007.09.007","volume":"22","author":"I Guti\u00e9rrez-Ca\u00f1as","year":"2008","unstructured":"Guti\u00e9rrez-Ca\u00f1as, I. et al. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav. Immun. 22, 312\u2013317 (2008).","journal-title":"Brain Behav. Immun."},{"key":"20400_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/0196-9781(84)90249-3","volume":"5","author":"O Andersen","year":"1984","unstructured":"Andersen, O., Fahrenkrug, J., Wikkelso, C. & Johansson, B. B. VIP in cerebrospinal fluid of patients with multiple sclerosis. Peptides 5, 435\u2013437 (1984).","journal-title":"Peptides"},{"key":"20400_CR38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1096\/fj.02-0475com","volume":"17","author":"Y Bangale","year":"2003","unstructured":"Bangale, Y. et al. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J. 17, 628\u2013635 (2003).","journal-title":"FASEB J."},{"key":"20400_CR39","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.humimm.2013.06.028","volume":"74","author":"MV Correa","year":"2013","unstructured":"Correa, M. V. et al. Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy. Hum. Immunol. 74, 1375\u20131381 (2013).","journal-title":"Hum. Immunol."},{"key":"20400_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/rheumatology\/kep134","volume":"48","author":"ZA El-Sayed","year":"2009","unstructured":"El-Sayed, Z. A. et al. Cardiovascular autonomic function assessed by autonomic function tests and serum autonomic neuropeptides in Egyptian children and adolescents with rheumatic diseases. Rheumatology (Oxford) 48, 843\u2013848 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"20400_CR41","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.clinbiochem.2012.08.020","volume":"45","author":"W Jiang","year":"2012","unstructured":"Jiang, W. et al. Expression of synovial fluid and articular cartilage VIP in human osteoarthritic knee: a new indicator of disease severity? Clin. Biochem. 45, 1607\u20131612 (2012).","journal-title":"Clin. Biochem."},{"key":"20400_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12929-016-0280-1","volume":"23","author":"W Jiang","year":"2016","unstructured":"Jiang, W., Wang, H., Li, Y. S. & Luo, W. Role of vasoactive intestinal peptide in osteoarthritis. J. Biomed. Sci. 23, 63 (2016).","journal-title":"J. Biomed. Sci."},{"key":"20400_CR43","doi-asserted-by":"publisher","first-page":"e43661","DOI":"10.1371\/journal.pone.0043661","volume":"7","author":"A Lamana","year":"2012","unstructured":"Lamana, A. et al. The TT genotype of the STAT4rs7574865 polymorphism is associated with high disease activity and disability in patients with early arthritis. PLoS One 7, e43661 (2012).","journal-title":"PLoS One"},{"key":"20400_CR44","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/ard.2009.114934","volume":"69","author":"B Skinningsrud","year":"2010","unstructured":"Skinningsrud, B. et al. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis. Ann. Rheum. Dis. 69, 1471\u20131474 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"20400_CR45","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1161\/ATVBAHA.108.172288","volume":"28","author":"R Burkhardt","year":"2008","unstructured":"Burkhardt, R. et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler. Thromb. Vasc. Biol. 28, 2078\u20132084 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"20400_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/CIRCULATIONAHA.108.773267","volume":"118","author":"MW Medina","year":"2008","unstructured":"Medina, M. W., Gao, F., Ruan, W., Rotter, J. I. & Krauss, R. M. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118, 355\u2013362 (2008).","journal-title":"Circulation"},{"key":"20400_CR47","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473\u20133478 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20400_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tig.2006.01.003","volume":"22","author":"VN Kim","year":"2006","unstructured":"Kim, V. N. & Nam, J. W. Genomics of microRNA. Trends Genet. 22, 165\u2013173 (2006).","journal-title":"Trends Genet."},{"key":"20400_CR49","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.tcb.2006.12.007","volume":"17","author":"RS Pillai","year":"2007","unstructured":"Pillai, R. S., Bhattacharyya, S. N. & Filipowicz, W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17, 118\u2013126 (2007).","journal-title":"Trends Cell Biol."},{"key":"20400_CR50","doi-asserted-by":"publisher","first-page":"e112646","DOI":"10.1371\/journal.pone.0112646","volume":"9","author":"F Paladini","year":"2014","unstructured":"Paladini, F. et al. Single nucleotide polymorphisms in the 3\u2032UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p. PLoS One 9, e112646 (2014).","journal-title":"PLoS One"},{"key":"20400_CR51","doi-asserted-by":"publisher","first-page":"e0141351","DOI":"10.1371\/journal.pone.0141351","volume":"10","author":"U Vosa","year":"2015","unstructured":"Vosa, U., Esko, T., Kasela, S. & Annilo, T. Altered Gene Expression Associated with microRNA Binding Site Polymorphisms. PLoS One 10, e0141351 (2015).","journal-title":"PLoS One"},{"key":"20400_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/jcmm.12716","volume":"20","author":"E Morini","year":"2016","unstructured":"Morini, E. et al. The human rs1050286 polymorphism alters LOX-1 expression through modifying miR-24 binding. J. Cell. Mol. Med. 20, 181\u2013187 (2016).","journal-title":"J. Cell. Mol. Med."},{"key":"20400_CR53","first-page":"2116","volume":"20","author":"J Esteve-Vives","year":"1993","unstructured":"Esteve-Vives, J., Batlle-Gualda, E. & Reig, A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptacion del HAQ a la Poblacion Espanola. J. Rheumatol. 20, 2116\u20132122 (1993).","journal-title":"J. Rheumatol."},{"key":"20400_CR54","doi-asserted-by":"publisher","first-page":"e29492","DOI":"10.1371\/journal.pone.0029492","volume":"6","author":"I Gonz\u00e1lez-\u00c1lvaro","year":"2011","unstructured":"Gonz\u00e1lez-\u00c1lvaro, I. et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One 6, e29492 (2011).","journal-title":"PLoS One"},{"key":"20400_CR55","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett, F. C. et al. The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315\u2013324 (1988).","journal-title":"Arthritis Rheum."},{"key":"20400_CR56","first-page":"S12","volume":"22","author":"KN Verpoort","year":"2004","unstructured":"Verpoort, K. N. et al. Undifferentiated arthritis\u2013disease course assessed in several inception cohorts. Clin. Exp. Rheumatol. 22, S12\u201317 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"20400_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.berh.2008.08.001","volume":"23","author":"K Raza","year":"2009","unstructured":"Raza, K. & Filer, A. Predicting the development of RA in patients with early undifferentiated arthritis. Best Pract. Res. Clin. Rheumatol. 23, 25\u201336 (2009).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"20400_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/art.22380","volume":"56","author":"AH van der Helm-van Mil","year":"2007","unstructured":"van der Helm-van Mil, A. H. et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 56, 433\u2013440 (2007).","journal-title":"Arthritis Rheum."},{"key":"20400_CR59","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1002\/art.11269","volume":"48","author":"MA Quinn","year":"2003","unstructured":"Quinn, M. A. et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum. 48, 3039\u20133045 (2003).","journal-title":"Arthritis Rheum."},{"key":"20400_CR60","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.1780351003","volume":"35","author":"DT Felson","year":"1992","unstructured":"Felson, D. T., Anderson, J. J. & Meenan, R. F. Use of short-term efficacy\/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 35, 1117\u20131125 (1992).","journal-title":"Arthritis Rheum."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20400-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:51:11Z","timestamp":1671587471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20400-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20400"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20400-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"24 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2035"}}